Souhaitez-vous accéder aux communiqués récents ?

Latest developments expand Predictive’s AI-driven drug discovery platform to include biomarker discovery and drug repurposing With the global biomarker discovery market valued at $14.5 billion in...

Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

New indications discovered by applying active machine learning and using samples from the company’s vast biobank of live-cell tumors specimens Builds upon Predictive’s biomarker discovery platform...

PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities,...

Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan Tumor response models for novel compounds...

Deal positions STREAMWAY® Systems with an established market leader to drive accelerating growth Transaction allows Predictive Oncology to be highly focused on its core AI-driven drug discovery...

Predictive receives first tranche of financing to initiate integration of AI/ML platform technologies, core laboratory capabilities and business development efforts in Europe and the United States ...

PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its...

PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today announced...

Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types Creates significant business development opportunities...